Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid

Alzheimer's disease (AD) therapies predominantly focus on β-amyloid (Aβ), but Aβ effects may be maximal before clinical symptoms appear. Downstream of Aβ, dendritic spine loss correlates most strongly with cognitive decline in AD. Rho-associated kinases (ROCK1 and ROCK2) regulate the actin cyto...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science signaling 2019-06, Vol.12 (587)
Hauptverfasser:	Henderson, Benjamin W, Greathouse, Kelsey M, Ramdas, Raksha, Walker, Courtney K, Rao, Tejeshwar C, Bach, Svitlana V, Curtis, Kendall A, Day, Jeremy J, Mattheyses, Alexa L, Herskowitz, Jeremy H
Format:	Artikel
Sprache:	eng
Schlagworte:	Actin Alzheimer's disease Brain Clinical trials Cognitive ability Cytoskeleton Degeneration Dementia Dementia disorders Dendritic spines Dendritic structure Downstream effects Hippocampus Inhibitors Kinases LIM kinase Medical research Morphology Myosin Neurodegeneration Neuroimaging Oligomers Patients Pharmacology Protein-serine/threonine kinase Resilience Senile plaques Signs and symptoms Spine Transgenic mice β-Amyloid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!